ClinicalTrials.gg
Not yet recruitingNCT06287086Updated Jun 3, 2024

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

An interventional study of BRL-101 autologous hematopoietic stem and progenitor cells injection in Sickle Cell Disease, sponsored by Bioray Laboratories. Not yet recruiting. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Bioray Laboratories · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
3 Years to 35 Years
Sex
All
01

Study summary

This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)

Read the detailed description

This clinical trial is a single-arm, single-dose, single center, open-label study without dose escalation. The primary objective is to explore the safety of the study drug in SCD. Myeloablative conditioning and administration for the remaining subjects can only be started after the first subject completes dosing and safety observation and assessment.

02

Conditions studied

  • Sickle Cell Disease

Browse trials for

03

In context

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

This study's planned enrollment of 1 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.

Browse Anemia, Sickle Cell studies →

Lead sponsor

Bioray Laboratories is the lead sponsor of 24 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all the following inclusion criteria to be eligible for enrolment into the study:

  1. Subject (or their legally authorized representative or guardian) will sign and date an form (ICF) and, where applicable, an assent form.
  2. Subjects 3 to 35 years of age, inclusive, on the date of informed consent.
  3. Clinically confirmed severe SCD, genotypes include: βS/βS, βS/β + or βS/β0. Severe SCD is defined as having at least 2 VOC events per year during the 2 years prior to screening and requiring appropriate supportive care, including a pain management program, HU therapy (if indicated).
  4. performance status of ≥80% for subjects ≥16 years of age. Lansky performance status of ≥80% for subjects \<16 years of age (see Appendix 1 and 2).
  5. Eligible for stem cell transplant as per investigator's judgment.
  6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, guidelines, and other study procedures.
  7. Willing to participate in an additional long-term follow-up study after completion of this study (Study 2022-LTF-BRL-101).
  8. Subjects of must use effective contraception for at least 6 months after BRL-101 infusion during the study.

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following criteria are not eligible for enrolment in the study:

  1. Known , intolerance, or to hematopoietic stem cell mobilizers, busulfan injection, or dimethyl sulfoxide (DMSO) or study drug-related components.
  2. Eligible for hematopoietic stem cell transplantation and have found HLA-identical donors.
  3. Prior allo-HSCT, gene therapy or gene editing therapy.
  4. and active bacterial, viral, fungal, or parasitic infection as determined by the investigator.
  5. HbF level >15.0%, irrespective of concomitant treatment with HbF inducing treatments such as HU.
  6. Treatment with regular RBC transfusions that, in the opinion of the investigator, cannot be interrupted after engraftment.
  7. More than 10 unplanned hospitalizations or emergency department visits related to SCD in the 1 year before screening and the investigator considered this to be a significant chronic pain rather than an acute pain crisis.
  8. A history of clinically significant transcranial Doppler (TCD) test abnormalities or test abnormalities in the opinion of the investigator.
  9. History of untreated Moyamoya disease or presence of Moyamoya disease at Screening that in the opinion of the investigator puts the subjects at the risk of bleeding.
  10. the subject has participated in other clinical studies and used drugs within 3 months before screening.
  11. White blood cell count \< 3 × 109/L and/or count \< 100 × 109/L not due to hypersplenism as judged by the investigator.
  12. > 1.5×, APTT > 1.5×ULN.
  13. Creatinine > 1.5 × ULN or endogenous \< 60 ml/min (calculated according to the Cockcroft-Gault formula, see Appendix 3).
  14. or AST> 3×ULN, or direct value > 2.5×ULN.
  15. Severe iron overload with serum ferritin ≥ 5000 ng/ml, liver iron > 15 mg Fe/g dry weight (or liver MRIT2* \< 1.4 ms or > 588 Hz), or heart MRI-T2* \< 10 ms.
  16. \< 50%.
  17. DLco \< 50% predicted (corrected or/and alveolar volume) or forced vital capacity (FVC) (measured/predicted) \< 60% (For children for whom DLco could not be determined), or abnormal blood gas analysis (for younger children with undetectable ventilatory function only).
  18. virus surface antigen (HBsAg) positive or HBV-DNA positive; virus (HCV) antibody positive; (HIV) antibody positive; syphilis (TP) -specific antibody positive; Epstein-Barr virus EBV-DNA positive; cytomegalovirus CMV-DNA positive.
  19. History of a significant bleeding disorder.
  20. History or family history of or myeloproliferative disorder.
  21. Any prior or current cardiovascular system diseases, such as congestive heart failure, arrhythmia, myocardial disease, valvular heart disease or pulmonary hypertension; cirrhosis, liver fibrosis or active hepatitis; central nervous system diseases or mental illness.
  22. Presence of immune dysfunction or endocrine disorders, such as insulin-dependent diabetes mellitus, hyperthyroidism, or insufficiency.
  23. Pregnant or breastfeeding females.
  24. Any condition that, in the opinion of the investigator, would make participation in this clinical study inappropriate.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Experimental
    BRL-101

    BRL-101 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the BCL11A gene. Subjects will receive a single infusion of BRL-101.

    Drug: BRL-101 autologous hematopoietic stem and progenitor cells injection

Interventions

  • DrugBRL-101 autologous hematopoietic stem and progenitor cells injection

    Drug pages: BRL-101 · Stem Cell

    CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.

    Also known as: BRL-101

06

What researchers measure

Primary outcomes

  1. Proportion of stem cell engrafted subjects

    Stem cell engraftment was defined as an absolute peripheral blood neutrophil count of ≥ 0.5 × 109/L for 3 consecutive days following BRL-101 intravenous infusion.

    Time frame: Within 42 Days After BRL-101 Infusion

  2. Time to neutrophil engraftment

    Defined as Day 1 of absolute peripheral blood neutrophil count ≥ 0.5 × 109/L for 3 consecutive days

    Time frame: Within 42 Days After BRL-101 Infusion

  3. Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusion..

    Adverse events assessed according to NCI-CTCAE v5.0 criteria

    Time frame: Within 12 Months After BRL-101 Infusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Aug 2025, 14 months later.

Of 173 interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Feb 29, 2024
StartEst.
Jun 14, 2024
Primary completionEst.
Aug 20, 2025
CompletionEst.
Jun 10, 2026
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06287086
Collaborators
Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Jun 14, 2024 (estimated)
Primary completion
Aug 20, 2025 (estimated)
Completion
Jun 10, 2026 (estimated)
Last update
Jun 3, 2024

Study contacts

Jun shi, PhD
Contact
shijun@ihcams.ac.cn
13752253515
Jun shi, PhD
study chair · Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BRL-101 · Stem Cell

Start the discussion